Identification of Vulnerability Factors in the Course of Pemphigus Patients (SHS-Pemphigus)

August 29, 2017 updated by: University Hospital, Rouen

Identification of Vulnerability Factors in the Course of Pemphigus Patients - SHS Pemphigus Clinical Trial

The bullous pemphigoid treatment is based on corticosteroids continued for several years. Pemphigus causes some patients a psychological impact and sometimes major vulnerability that can occur not only at diagnosis but also at later stages of disease progression. Our hypothesis is that these episodes of vulnerability may be under four kinds of factors that may be connected to the plurality of the history of these patients, and the resources they can mobilize throughout this experience, generating inequality in management and "work" around the disease.

Study Overview

Detailed Description

The originality of the project lies in its multidisciplinary approach (dermatology, psychology, sociology). No such study has yet been carried out in the pemphigus who has been the subject of a very small number of works in sociology or psychology. The only studies are studies of quality of life with no longitudinal follow-up. The perspective of qualitative and quantitative data, sociological and psychological approaches, should allow more innovative and adapted to the medico-social and psychological care of patients with pemphigus approaches. The purpose of this study is to identify the determinants leading to moments of vulnerability in the course of patients with pemphigus in order to be able to offer preventive or corrective actions to improve the experience of the disease.

Study Type

Interventional

Enrollment (Anticipated)

48

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Bobigny, France, 93000
        • Recruiting
        • Hôpital Avicenne
        • Contact:
        • Principal Investigator:
          • Catherine PROST-SQUARCIONI, professor
      • Clermont-Ferrand, France, 63003
        • Recruiting
        • CHU de Clermont-Ferrand Hôpital d'Estaing
        • Contact:
        • Principal Investigator:
          • Michel D'Incan, Professor
      • Lille, France, 59037
        • Recruiting
        • Chru de Lille Hopital Claude Huriez
        • Contact:
        • Principal Investigator:
          • Emmanuel DELAPORTE, Professor
      • Marseille, France
        • Recruiting
        • Hôpital La Timone, Assistance publique hôpitaux de Marseille-Aix
        • Contact:
          • Marie-Aleth RICHARD LALLEMAND, Professor
          • Phone Number: +33 4 91 38 79 91
          • Email: mrichard@ap-hm.fr
        • Principal Investigator:
          • Marie Alteh RICHARD LALLEMAND, Professor
      • Pessac, France, 33604
      • Quimper, France, 29107
        • Recruiting
        • Centre Hospitalier de Cornouaille
        • Contact:
        • Principal Investigator:
          • Ingrid KUPFER-BESSAGUET, Doctor
      • Reims, France, 51 092
        • Recruiting
        • Hôpital Robert Debré, chu de Reims
        • Contact:
        • Principal Investigator:
          • Philippe BERNARD, Professor
      • Rouen, France, 76031
        • Recruiting
        • University Hospital of Rouen
        • Contact:
        • Sub-Investigator:
          • Sophie DUVERT LEHEMBRE, Doctor
      • le Mans, France, 72037
        • Recruiting
        • CH du Mans
        • Contact:
        • Principal Investigator:
          • Hervé MAILLARD, Professor

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patient major
  • Patients with pemphigus vulgaris, diagnosed on a combination of:

    1. clinical signs and
    2. histological image above basal epithelial detachment with intra acantholysis,
    3. direct immunofluorescence showing deposition of Immunoglobulin G and / or C3 to the surface of keratinocytes
  • Join a social security scheme
  • patient has been informed and have signed consent to participate in the study

Exclusion Criteria:

  • Person placed under judicial protection,
  • Patient without liberty by administrative or judicial decision,
  • Patient participating in another trial for the duration of monitoring.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: prevalent cases

40 prevalent cases correspond to patients with known pemphigus. Emphasis will be on included patients at different times of the course of their disease.

8 incident cases recruited through the center of Rouen and following an intervention program with psychological support and therapeutic education program

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
analysis of vulnerability factors
Time Frame: 12 months
evaluation of : perception by the patient of misdiagnosis, perception of a possible difference in assessment of the severity of his illness between himself and healthcare professionals, patient behavior in relation to available information sources, and the influence of information gathered on the illness experience, Patient trajectory during the diagnostic phase using individual interview and questionnaire
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
analysis of vulnerability factors
Time Frame: 6 months
evaluation of : perception by the patient of misdiagnosis, perception of a possible difference in assessment of the severity of his illness between himself and healthcare professionals, patient behavior in relation to available information sources, and the influence of information gathered on the illness experience, Patient trajectory during the diagnostic phase using individual interview and questionnaire
6 months
assessment of anxiety, uncertainty, fear, coping strategies
Time Frame: 12 months
assessment of anxiety, uncertainty, fear, coping strategies using individual interview and questionnaire
12 months
assessment of anxiety, uncertainty, fear, coping strategies
Time Frame: 6 months
assessment of anxiety, uncertainty, fear, coping strategies using individual interview and questionnaire
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Pascal Joly, Professor, University Hospital, Rouen

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2015

Primary Completion (Anticipated)

May 1, 2018

Study Completion (Anticipated)

November 1, 2018

Study Registration Dates

First Submitted

September 1, 2014

First Submitted That Met QC Criteria

September 8, 2014

First Posted (Estimate)

September 11, 2014

Study Record Updates

Last Update Posted (Actual)

August 30, 2017

Last Update Submitted That Met QC Criteria

August 29, 2017

Last Verified

August 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • 2014/063/HP
  • 2014A0067740 (Registry Identifier: RCB number)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pemphigus

Clinical Trials on psychological support and therapeutic education program

3
Subscribe